Metabolomics of IgE-Mediated Food Allergy and Oral Immunotherapy Outcomes based on Metabolomic Profiling

Abstract

Background The immunometabolic mechanisms underlying variable responses to oral immunotherapy (OIT) in patients with IgE-mediated food allergy are unknown.

Objective To identify novel pathways associated with tolerance in food allergy, we used metabolomic profiling to find pathways important for food allergy in multi-ethnic cohorts and responses to OIT.

Methods Untargeted plasma metabolomics data were generated from the VDAART healthy infant cohort (N=384), a Costa Rican cohort of children with asthma (N=1040), and a peanut OIT trial (N=20) evaluating sustained unresponsiveness (SU, protection that lasts after therapy) versus transient desensitization (TD, protection that ends immediately afterwards). Generalized linear regression modeling and pathway enrichment analysis identified metabolites associated with food allergy and OIT outcomes.

Results Compared with unaffected children, those with food allergy were more likely to have metabolomic profiles with altered histidines and increased bile acids. Eicosanoids (e.g., arachidonic acid derivatives) (q=2.4×10⁻²⁰) and linoleic acid derivatives (q=3.8×10⁻⁵) pathways decreased over time on OIT. Comparing SU versus TD revealed differing concentrations of bile acids (q=4.1×10⁻⁸), eicosanoids (q=7.9×10⁻⁷), and histidine pathways (q=0.015). In particular, the bile acid lithocholate (4.97[1.93,16.14], p=0.0027), the eicosanoid leukotriene B4 (3.21[1.38,8.38], p=0.01), and the histidine metabolite urocanic acid (22.13[3.98,194.67], p=0.0015) were higher in SU.

Conclusions We observed distinct profiles of bile acids, histidines, and eicosanoids that vary among patients with food allergy, over time on OIT and between SU and TD. Participants with SU had higher levels of metabolites such as lithocholate and urocanic acid, which have immunomodulatory roles in key T-cell subsets, suggesting potential mechanisms of tolerance in immunotherapy.

• – Compared with unaffected controls, children with food allergy demonstrated higher levels of bile acids and distinct histidine/urocanic acid profiles, suggesting a potential role of these metabolites in food allergy.

• – In participants receiving oral immunotherapy for food allergy, those who were able to maintain tolerance-even after stopping therapyhad lower overall levels of bile acid and histidine metabolites, with the exception of lithocholic acid and urocanic acid, two metabolites that have roles in T cell differentiation that may increase the likelihood of remission in immunotherapy.

Capsule summary This is the first study of plasma metabolomic profiles of responses to OIT in individuals with IgE-mediated food allergy. Identification of immunomodulatory metabolites in allergic tolerance may help identify mechanisms of tolerance and guide future therapeutic development.

• Download figure
• Open in new tab

Competing Interest Statement

JLS is a scientific consultant to Precion Inc. and TruDiagnostic Inc. AAL contributes to UpToDate, Inc, author of online education, royalties totaling not more than $3000 per year. STW receives royalties from UpToDate and is on the board of Histolix a digital pathology company. JCC has received research materials (inhaled steroids) from Merck, in order to provide medications free of cost to participants in an NIH-funded study, unrelated to the current work. The remaining authors have no conflicts of interest to disclose.

Funding Statement

The Genetics of Asthma in Costa Rica Study was supported by the National Institutes of Health (Grants HL066289, P01HL13225, R01HL123915). Vitamin D Antenatal Asthma Reduction Trial (VDAART) was supported by R01HL123546, R01HL091528, U01HL091528, and UH3ODO023268 from the National Heart, Lung, and Blood Institute (NHLBI); U54TR001012 from the National Centers for Advancing Translational Sciences; and U19AI168643 from the NIAID. GACRS & VDAART metabolomic profiling and additional analyses were supported by R01HL123915, R01HL141826, and R01HL155742. The Peanut Oral Immunotherapy (PNOIT) study clinical trial work was performed at the Harvard Clinical and Translational Science Center supported by Grant Numbers 1UL1TR001102, 8UL1TR000170 from the National Center for Advancing Translational Science, and 1UL1 RR025758 from the National Center for Research Resources. PNOIT metabolomics profiling was supported by the 2014 ARTrust Minigrant. This work is also supported by NIH NIAID (grant K23-AI130408 for YVV, T32AI007062 for JNS, 1R01AI155630 for SUP), and NHLBI (K01 HL146980 for RSK). CEW was supported by the Swedish Heart-Lung Foundation (HLF 20230463, HLF 20210519). SB is supported by the NIH NIAID (UM1 AI173380, U19 AI136053, R01 AI147028, U01 AI160082). EB is supported by NIEHS (P42ES027704) and NIGMS (R01GM141277 and RM1GM145416).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Massachusetts General Hospital and Brigham & Women's Hospital Institutional Review Boards gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes